Navigation Links
MRSA study suggests strategy shift needed to develop effective therapeutics

USA300the major epidemic strain of methicillin-resistant Staphylococcus aureus (MRSA) causing severe infections in the United States during the past decadeinherits its destructiveness directly from a forefather strain of the bacterium called USA500 rather than randomly acquiring harmful genes from other MRSA strains. This finding comes from a new study led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The study authors suggest that a radical shift may be needed in how scientists should design MRSA therapeutics. Instead of the current focus on neutralizing MRSA by targeting products of mobile genetic elementsDNA molecules that bacteria acquire randomly by interacting with other bacteriascientists should switch to looking at the permanent DNA backbone (core genome) of USA300 to understand how increased production of certain proteins such as toxins affects its virulence in humans.

NIAID scientist Michael Otto, Ph.D., directed the study, which involved analyzing DNA sequences of the major epidemic forms of S. aureus. The research team found that the lineage of the bacteria fell into three distinct families: (1) USA300 and its forefather, USA500, which are epidemic in U.S. hospital and community settings; (2) MRSA found primarily in hospitals in the United Kingdom and Europe; and (3) MRSA found in hospitals in South America, Europe and Asia.

The researchers then tested the different lineages in mice, observing that the USA300 and USA500 strains were significantly more destructive than the other strains. Further, when interacting with human immune cells, the USA300 and USA500 strains killed nearly 80 percent of the immune cells, compared with a rate of less than 10 percent for all other strains tested. Finally, when the scientists evaluated what in the bacteria was killing the immune cells, they found that levels of alpha toxin and alpha-type phenol-soluble modulins (PSMs) were significantly higher in USA300 and USA500 compared with the other strains. Earlier NIAID studies determined that alpha toxin and alpha-type PSMs play a crucial role in determining the severity of community-associated MRSA infection.

Another important finding of the study, according to Dr. Otto, is that USA300 and USA500 are nearly identical in virulence, as is their level of virulence gene production. This suggests that the Panton-Valentine leukocidin (PVL) and other mobile genetic elements long believed to play key roles in USA300 virulence have no significant impact, because while USA300 carries the PVL and other mobile genes, USA500 does not.


Contact: Ken Pekoc
NIH/National Institute of Allergy and Infectious Diseases

Related medicine news :

1. Study tracks increasing use of CT on pregnant women
2. First sister study results reinforce the importance of healthy living
3. Tens of Thousands of Back Pain Patients Overtreated in Six Health Plans, According to HealthCore Study
4. Study Finds that Dying Patients and Families Suffer from Lack of Continuity of Physician Care
5. New Clinical Study Finds Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Accurate in the Noninvasive Monitoring of Fluid Status During Surgery
6. Firefighters Have Narrower-Than-Normal Arteries, Study Finds
7. Drugs Before Stents for Stable Heart Disease, Study Says
8. New Study Shows Probiotic Strain Effective in Boosting Immune Response
9. Studying the female form
10. Aspirin improves survival in women with stable heart disease, according to WHI study
11. New Study Finds PFOA Levels in Drinking Water Are Safe
Post Your Comments:
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: